38.6% of adults below the poverty line carry high cardiovascular-risk inflammation levels. Among higher-income adults, that number is 24.0%. That 14.6-percentage-point gap isn't explained away by obesity or smoking. It persists even among normal-weight people who have never smoked.

High-sensitivity C-reactive protein (hsCRP) is a blood marker of systemic inflammation. Levels above 3 mg/L signal elevated cardiovascular risk. What NHANES data show is that this threshold isn't crossed randomly across the population. It follows income, almost perfectly.

The Gradient Is Stepwise, Not a Cliff

The income-inflammation relationship doesn't just separate the poor from everyone else. It runs continuously up the income ladder. High cardiovascular-risk hsCRP prevalence sits at 38.6% below the poverty line, drops to 33.4% in the near-poverty band, falls further to 30.5% in the middle-income range, and reaches 24.0% among adults with an income-to-poverty ratio of 4.0 or above.

Each income step carries a measurable reduction in inflammatory burden. The weighted mean hsCRP follows the same pattern: 2.85 mg/L below poverty, declining to 2.12 mg/L at higher incomes. That difference may look modest in absolute terms, but at the population level, a sustained shift of that magnitude in a cardiovascular risk marker translates to meaningful differences in heart attack and stroke rates over time.

What makes this finding harder to dismiss is what happens when you control for the most obvious confounders. Among normal-weight adults who have never smoked, a group where obesity and cigarettes can't explain the gap, weighted mean hsCRP still runs at 2.06 mg/L below poverty versus 1.53 mg/L among higher-income counterparts. The gradient survives the most conservative comparison the data allow.

When Risk Factors Stack, Income Amplifies Everything

The clearest signal in the data comes from the highest-risk subgroup: obese current smokers. Below the poverty line, this group has a weighted mean hsCRP of 8.49 mg/L. Among obese current smokers in the higher-income group, the figure is 3.51 mg/L. That's a 2.4-fold difference between people who share the same two major behavioral risk factors, separated only by income.

This matters because it reframes how we think about risk stratification. Two patients with identical BMI and smoking status can carry dramatically different inflammatory profiles depending on where they sit on the income scale. A clinical model that treats obesity and smoking as the primary drivers of hsCRP elevation, without accounting for income, will systematically underestimate cardiovascular risk among low-income patients.

Race Complicates the Income Story

For Non-Hispanic White adults, the income gradient is clean. Elevated hsCRP prevalence runs from 39.4% below poverty down to 24.8% in the 4.0-5.0 income band, a 14.6-point decline across the income spectrum.

Non-Hispanic Black adults show a different pattern. Elevated hsCRP prevalence is 35.4% below poverty, but rises to 44.4% in the near-poverty band before declining to 28.3% at higher incomes. The gradient doesn't run in one direction. Near-poverty Black adults carry a higher inflammatory burden than those below the poverty line, a reversal that doesn't appear in any other racial group in this data.

Non-Hispanic Asian adults occupy the opposite extreme. Their weighted mean hsCRP ranges from 1.30 to 1.64 mg/L across all income bands, the lowest of any group regardless of income. Mexican American adults below poverty have a weighted mean hsCRP of 3.12 mg/L, higher than the overall below-poverty average of 2.85 mg/L.

These racial patterns mean the income-inflammation relationship isn't uniform. For Non-Hispanic White adults, more income reliably means less inflammation. For Non-Hispanic Black adults, the relationship is non-linear in a way the data alone can't resolve. Whether rising income in the near-poverty range confers the same inflammatory protection for Black Americans as it does for White Americans remains an open question with direct consequences for how cardiovascular risk is modeled, screened, and treated across populations.